Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Haplotype-resolved DNA methylation at the <i>APOE</i> locus identifies allele-specific epigenetic signatures relevant to Alzheimer's disease risk.

NPJ dementia·2026

Same author

Is SORL1 a common genetic target across neurodegenerative diseases? A multi-ancestry biobank study.

Brain : a journal of neurology·2026

Same author

Region-specific transcriptional signatures of brain aging in the absence of neuropathology at the single-cell level.

npj aging·2026

Same author

The complete genome of the KOLF2.1J reference iPSC line.

bioRxiv : the preprint server for biology·2026

Same author

Sex effects on gene expression across the human cerebral cortex at cell type resolution.

Science (New York, N.Y.)·2026

Same author

Inflammatory signaling differentially changes chromatin accessibility and gene expression of the PD- associated kinase LRRK2 between human and mice.

Molecular neurodegeneration·2026

Same journal

Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice.

Molecular neurodegeneration·2026

Same journal

Standardized protocol to detect phosphorylated α-synuclein in skin biopsies: recommendations from an expert panel.

Molecular neurodegeneration·2026

Same journal

A 'Tangled Web' in the CNS: unraveling neutrophil extracellular traps in neurological disorders.

Molecular neurodegeneration·2026

Same journal

Perspective of retinal Chlamydia pneumoniae infection in Alzheimer's disease pathogenesis.

Molecular neurodegeneration·2026

Same journal

A reappraisal of APOE genetic effects on Alzheimer's disease risk in the Japanese population: a meta-analysis.

Molecular neurodegeneration·2026

Same journal

Riboregulation: a non-canonical tau function.

Molecular neurodegeneration·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

alpha-Synuclein and neuronal cell death.

Mark R Cookson¹

¹Laboratory of Neurogenetics, National Institute on Aging, NIH, Building 35, Room 1A116, MSC 3707, 35 Convent Drive, Bethesda, MD 20982-3707, USA. cookson@mail.nih.gov.

Molecular Neurodegeneration

|February 6, 2009

Summary

This summary is machine-generated.

Alpha-synuclein protein is implicated in Parkinson disease pathogenesis. This review explores how alpha-synuclein toxicity contributes to neuronal death and discusses potential therapeutic strategies.

More Related Videos

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Published on: June 26, 2018

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

Related Experiment Videos

Last Updated: Jun 25, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Published on: June 26, 2018

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

Area of Science:

Neuroscience
Molecular Biology
Genetics

Background:

Alpha-synuclein is a protein found in Lewy bodies, a hallmark of Parkinson disease.
Mutations and increased expression of alpha-synuclein are linked to both familial and sporadic Parkinson disease.
Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra.

Purpose of the Study:

To review experimental evidence demonstrating alpha-synuclein toxicity.
To elucidate the mechanisms by which alpha-synuclein causes neuronal damage.
To discuss therapeutic implications related to alpha-synuclein toxicity.

Main Methods:

Review of experimental studies on alpha-synuclein.
Analysis of genetic and expression data related to alpha-synuclein.
Examination of cellular and molecular mechanisms of neurodegeneration.

Main Results:

Alpha-synuclein, particularly mutant forms or at elevated levels, is toxic to neurons.
Alpha-synuclein contributes to neuronal cell death in Parkinson disease.
Understanding alpha-synuclein toxicity is crucial for Parkinson disease research.

Conclusions:

Alpha-synuclein plays a central role in Parkinson disease pathology.
Further research into alpha-synuclein mechanisms can guide therapeutic development.
Targeting alpha-synuclein toxicity offers potential treatment avenues for Parkinson disease.